Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind placebo-controlled trial of larazotide acetate (AT-1001) in active celiac disease
2008-000415-14Phase 2Active
- Sponsor
- Alba Therapeutics
- Start
- Jul 2008
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in celiac disease comparing AT-1001 (larazotide acetate) with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jul 2008; status: active.
02
Drugs
larazotide
03
Conditions
celiac disease
Beyond the preview
Go deeper on 2008-000415-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000415-14.